Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874725 | 0.89 | ALDH1A1 (0.59) | ALDH1A1PKMKMT2AMEN1HTT | |
| SCHEMBL3879290 | 0.87 | ALDH1A1 (0.66) | ALDH1A1PKMKMT2AMEN1HTT | |
| SCHEMBL3875950 | 0.87 | TSHR (0.61) | ALDH1A1KMT2AHTTHDAC6SMN1; SMN2 | |
| SCHEMBL3875842 | 0.85 | HTT (0.75) | ALDH1A1HTTPOLBHDAC6CA2 | |
| SCHEMBL1927570 | 0.81 | MEN1 (0.83) | KMT2AMEN1POLBHDAC6SMN1; SMN2 | |
| SCHEMBL3883213 | 0.80 | CYP19A1 (0.57) | ALDH1A1HTTHDAC6SMN1; SMN2HDAC2 | |
| SCHEMBL3873119 | 0.80 | HTT (0.67) | ALDH1A1HTTPOLBHDAC6CA2 | |
| SCHEMBL3873636 | 0.80 | CYP19A1 (0.59) | HTTPOLBHDAC6CA2HDAC2 | |
| SCHEMBL3873253 | 0.79 | ALDH1A1 (0.55) | ALDH1A1PKMKMT2AMEN1HTT | |
| SCHEMBL3873960 | 0.78 | PKM (0.74) | ALDH1A1PKMKMT2AHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814846-B1 | 11BETA-HSD1 INHIBITORS | EVOTEC AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090069323-A1 | 11beta-hsdi inhibitors | EVOTEC AG (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1814846-A1 | 11BETA-HSD1 INHIBITORS | Evotec AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006048330-A1 | 11ΒΕΤΑ-HSD1 INHIBITORS | EVOTEC AG (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069323-A1 | 11beta-hsdi inhibitors | HSD3B1, HSD3B2, HSD11B1 | ALDH1A1 210/4885PKM 1568/4885KMT2A 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.